STAQ Pharma, Inc.: Drug Recall

Recall #D-0147-2024 · 11/29/2023

Class II: Risk

Recall Details

Recall Number: D-0147-2024
Classification: Class II
Product Type: Drug
Recalling Firm: STAQ Pharma, Inc.
Status: Completed
Date Initiated: 11/29/2023
Location: Denver, CO, United States
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 2616 bags

Reason for Recall

STAQ Pharma Inc. received consumer complaints related to leaking bags and other potential bag concerns. Upon investigation, they determine the source of the issue was with the bag manufacturer who released bags Lot # 134142-001A which had failed internal QC tests for leaks.

Product Description

ROPivacaine HCl 0.2% PF in Sodium Chloride 1,000 mg/500 mL (2 mg per mL) Injection, 500 mL bags, Rx only, STAQ Pharma Inc. 14135 E 42nd Ave, Unit 50, Denver, Colorado 80239, NDC 73177-0109-26,

Distribution Pattern

Nationwide within the United States

Other Recalls by STAQ Pharma, Inc.

Class III: Low Risk 10/09/2025

Labeling: Incorrect or Missing Lot and/or Exp Date
Class III: Low Risk 10/09/2025

Labeling: Incorrect or Missing Lot and/or Exp Date
Class III: Low Risk 10/09/2025

Labeling: Incorrect or Missing Lot and/or Exp Date
Class I: Dangerous 02/03/2022

Labeling: Label Mix up; A limited number of syringes containing HYDROmorphone HCl PF were incorrectly labeled as Morphine Sulfate PF with lot number 21104221A
Class I: Dangerous 02/03/2022

Labeling: Label Mix up; A limited number of syringes containing HYDROmorphone HCl PF were incorrectly labeled as Morphine Sulfate PF with lot number 21104221A

View all recalls by STAQ Pharma, Inc. →

Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.